Maintains Strong Growth Amid Global Health Focus
SIGA Technologies Posts Q2 2024 Earnings, Maintains Strong Growth Amid Global Health Focus
SIGA Technologies, Inc. (NASDAQ: SIGA) reported solid financial results for Q2 2024. The company posted revenue of $21.81 million, largely driven by sales of its flagship product, TPOXX®, an antiviral medication used for smallpox and mpox (monkeypox). Earnings per share (EPS) came in at $0.03, exceeding analyst expectations.
Financial and Market Performance
• Revenue: $21.81 million, showing steady product sales.
• EPS: $0.03, beating forecasts.
• Stock Performance: The stock is trading around $10.13, up significantly year-to-date, with a strong P/E ratio of 9.49 .
Future Outlook
Analysts forecast earnings growth of 23.76% over the next year, with EPS expected to rise to $1.25 in 2025. SIGA’s focus on infectious disease treatments and government contracts positions it well for continued growth.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
SIGA Technologies, Inc. (NASDAQ: SIGA) reported solid financial results for Q2 2024. The company posted revenue of $21.81 million, largely driven by sales of its flagship product, TPOXX®, an antiviral medication used for smallpox and mpox (monkeypox). Earnings per share (EPS) came in at $0.03, exceeding analyst expectations.
Financial and Market Performance
• Revenue: $21.81 million, showing steady product sales.
• EPS: $0.03, beating forecasts.
• Stock Performance: The stock is trading around $10.13, up significantly year-to-date, with a strong P/E ratio of 9.49 .
Future Outlook
Analysts forecast earnings growth of 23.76% over the next year, with EPS expected to rise to $1.25 in 2025. SIGA’s focus on infectious disease treatments and government contracts positions it well for continued growth.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.